146 related articles for article (PubMed ID: 29952413)
1. Long-term risk of rosiglitazone on cardiovascular events - a systematic review and meta-analysis.
Cheng D; Gao H; Li W
Endokrynol Pol; 2018; 69(4):381-394. PubMed ID: 29952413
[TBL] [Abstract][Full Text] [Related]
2. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
Singh S; Loke YK; Furberg CD
JAMA; 2007 Sep; 298(10):1189-95. PubMed ID: 17848653
[TBL] [Abstract][Full Text] [Related]
3. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes.
Griffin SJ; Leaver JK; Irving GJ
Diabetologia; 2017 Sep; 60(9):1620-1629. PubMed ID: 28770324
[TBL] [Abstract][Full Text] [Related]
4. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.
Wallach JD; Wang K; Zhang AD; Cheng D; Grossetta Nardini HK; Lin H; Bracken MB; Desai M; Krumholz HM; Ross JS
BMJ; 2020 Feb; 368():l7078. PubMed ID: 32024657
[TBL] [Abstract][Full Text] [Related]
5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
6. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
Dahabreh IJ; Economopoulos K
Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data.
Bain S; Druyts E; Balijepalli C; Baxter CA; Currie CJ; Das R; Donnelly R; Khunti K; Langerman H; Leigh P; Siliman G; Thorlund K; Toor K; Vora J; Mills EJ
Diabetes Obes Metab; 2017 Mar; 19(3):329-335. PubMed ID: 27862902
[TBL] [Abstract][Full Text] [Related]
9. Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.
Loebstein R; Dushinat M; Vesterman-Landes J; Silverman B; Friedman N; Katzir I; Kurnik D; Lomnicky Y; Kokia E; Halkin H
J Clin Pharmacol; 2011 Feb; 51(2):173-80. PubMed ID: 20484611
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone for type 2 diabetes mellitus.
Richter B; Bandeira-Echtler E; Bergerhoff K; Clar C; Ebrahim SH
Cochrane Database Syst Rev; 2007 Jul; 2007(3):CD006063. PubMed ID: 17636824
[TBL] [Abstract][Full Text] [Related]
11. Effects of intensive glucose lowering in treatment of type 2 diabetes mellitus on cardiovascular outcomes: A meta-analysis of data from 58,160 patients in 13 randomized controlled trials.
Fang HJ; Zhou YH; Tian YJ; Du HY; Sun YX; Zhong LY
Int J Cardiol; 2016 Sep; 218():50-58. PubMed ID: 27236108
[TBL] [Abstract][Full Text] [Related]
12. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
[TBL] [Abstract][Full Text] [Related]
13. Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone.
Mendes D; Alves C; Batel-Marques F
Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1259-70. PubMed ID: 26376779
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
Home PD; Pocock SJ; Beck-Nielsen H; Gomis R; Hanefeld M; Jones NP; Komajda M; McMurray JJ;
N Engl J Med; 2007 Jul; 357(1):28-38. PubMed ID: 17551159
[TBL] [Abstract][Full Text] [Related]
15. [Rosiglitazone: no increase in cardiovascular mortality].
Jazet IM; Meinders AE
Ned Tijdschr Geneeskd; 2009; 153():A942. PubMed ID: 19930745
[TBL] [Abstract][Full Text] [Related]
16. The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis.
Wu S; Cipriani A; Yang Z; Yang J; Cai T; Xu Y; Quan X; Zhang Y; Chai S; Sun F; Zhan S
Expert Opin Drug Saf; 2018 Mar; 17(3):243-249. PubMed ID: 29320889
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular risk of rosiglitazone: another perspective.
Waksman JC
J Pharm Pharmacol; 2008 Dec; 60(12):1573-82. PubMed ID: 19000361
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
19. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
Seidu S; Achana FA; Gray LJ; Davies MJ; Khunti K
Diabet Med; 2016 Mar; 33(3):280-9. PubMed ID: 26282461
[TBL] [Abstract][Full Text] [Related]
20. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal TP; Hemmingsen C; Wetterslev J
Cochrane Database Syst Rev; 2013 Nov; (11):CD008143. PubMed ID: 24214280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]